

MARKET REPORT



Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017

DelveInsight's, " Acute Renal Failure (ARF) (Acute Kidney Injury) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Acute Renal Failure (ARF) (Acute Kidney Injury). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Acute Renal Failure (ARF) (Acute Kidney Injury). This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Atox Bio Ltd

Cellmid Ltd

Complexa Inc

DiaMedica Therapeutics Inc

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

Kringle Pharma Inc

Mitotech SA

NephroGenex Inc

NeuroVive Pharmaceutical AB

Nyken BV

ProMetic Life Sciences Inc

Quark Pharmaceuticals Inc
Regulus Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Spherium Biomed SL
STATegics Inc
Stealth BioTherapeutics Inc
Thrasos Therapeutics Inc
Torrent Pharmaceuticals Ltd
Xigen SA

Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Assessment
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Analysis
Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs under Development
Acute Renal Failure (ARF) (Acute Kidney Injury) Discovery drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Preclinical drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Phase I drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Phase II drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Phase III Pipeline Drugs Assessment
Acute Renal Failure (ARF) (Acute Kidney Injury) Preregistration drugs
Acute Renal Failure (ARF) (Acute Kidney Injury) Molecules in pipeline

Additional Details

Publisher : Delve Insight
Reference : DIPI0007
Number of Pages : 70
Report Format : PDF
Publisher Information :

The advertisement features a person in a white lab coat and blue gloves holding a report cover. The report cover displays the DelveInsight logo, a cityscape, and the BioPortfolio title. The background is a blurred laboratory setting with test tubes and equipment.

DELVEINSIGHT
INSIGHTS DRUGS AND PATENTS

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017 [Report Updated: 10-07-2017]

- Report IntroductionAcute Renal Failure (ARF) (Acute Kidney Injury) OverviewPipeline TherapeuticsAn Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury)Comparative AnalysisProducts in Clinical StageDrug Name : Company NameProduct DescriptionResearch and DevelopmentProduct Development ActivitiesProducts in Pre-Clinical and Discovery StageDrug Name : Company NameProduct DescriptionResearch and DevelopmentProduct Development ActivitiesTherapeutic AssessmentAssessment by Route of AdministrationAssessment by Stage and Route of Administration Assessment by Molecule TypeAssessment by Stage and Molecule TypeInactive ProductsDrug Name : Company NameProduct DescriptionResearch and DevelopmentProduct Development ActivitiesAppendixReport MethodologyConsulting ServicesDisclaimerAbout DelveInsight

List Of Tables in Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017 [Report Updated: 10-07-2017]

Table 1: Total Products for Acute Renal Failure (ARF) (Acute Kidney Injury)

Table 2: Products in Clinical Stage

Table 3: Products in Pre-Clinical and Discovery Stage

Table 4: Assessment by Route of Administration

Table 5: Assessment by Stage and Route of Administration

Table 6: Assessment by Molecule Type

Table 7: Assessment by Stage and Molecule Type

Table 8: Inactive Products

List Of Figures, Charts and Diagrams in Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017 [Report Updated: 10-07-2017]

Figure 1: Total Products for Acute Renal Failure (ARF) (Acute Kidney Injury)

Figure 2: Products in Clinical Stage

Figure 3: Products in Pre-Clinical and Discovery Stage

Figure 4: Assessment by Route of Administration

Figure 5: Assessment by Stage and Route of Administration

Figure 6: Assessment by Molecule Type

Figure 7: Assessment by Stage and Molecule Type

Figure 8: Inactive Products

How to Buy...

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017 [Report Updated: 10-0-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/104570>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1500** | Single User Price
- \$3000** | Site License Price
- \$4500** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.